$10 Billion Deal, page-11884

First 11884 Last

Share
Profile

Follow
fishman67

4,216 Posts.

666

25/10/23

02:36

Post #: 70517485
Share

Originally posted by ArielStarr89 ↑

MM = Has participated along with all the other directors in their full entitlement in the last CR great leap of faith they have their money where their mouth is.

MM has been working and enhancing BIT225 over the last 20 years.

MM dropping statements such as

MM mentioning we looking forward to the new year with confidence. along with 'we believe BIT225 is close to the finish line '

If people read what MM has provided in a previous report below you wont be taking BIT225 lightly.

One of the main problems in trying to cure HIV is the
nature of the immune cells the virus infects. Its major
target is a type of white blood cell known as the CD4 cell
that has several important roles in the immune system.
These include marshalling immune responses to attack
foreign agents such as viruses and “remembering”
previous infections.

Subsets of CD4 cells can, in effect, store a record of
known infections, but the problem is that that these cells
can become dormant and live in the body indefinitely.
Once these cells are infected with HIV, the virus can
continue to survive in the body by hiding in these
dormant CD4 cells.

Other cells, such as macrophages, are also targets for
HIV-1 infection. Virus in these macrophage cells as well
as in the dormant CD4 cells is hidden from the immune
system meaning that anti-HIV drugs can never truly
eradicate the infection from these reservoirs. Patients
infected with HIV-1 must remain on treatment for life.
In March, we reported that Biotron had discovered a way
for these hidden HIV-infected cells to be found, allowing
the immune system to attack and kill the virus.

We conducted a Phase 2 randomised placebo-controlled
clinical trial on 36 HIV-1 infected patients in Thailand in
which we tested BIT225 in combination with Atripla, an
approved current anti-HIV drug (ART). As reported to the
market in late 2018, we saw unexpected, unique changes
in the profiles of key immune cell populations in the
BIT225 + ART group

Expand

Is it ERADICATED or did the Virus find another hide out???? The fact we are the first company in over 40 years to have a crack at flushing out and unmasking the Virus is pretty cool……to think there are people on the outside of the world that want to kill each other beggars belief

BIT Price at posting: 8.2¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 1,453 more messages in this thread...

First 11884 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 1.9¢		Change 0.000(0.00%)		Mkt cap ! $17.14M

Open	High	Low	Value	Volume
1.9¢	1.9¢	1.8¢	$44.24K	2.352M

Buyers (Bids)

No.	Vol.	Price($)
2	962137	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.0¢	950263	4

View Market Depth

No.	Vol.	Price($)
2	962137	0.019
11	1761414	0.018
9	928388	0.017
13	3259350	0.016
7	865000	0.015

Price($)	Vol.	No.
0.020	950263	4
0.021	555000	2
0.022	997769	4
0.023	1449422	4
0.024	153949	2

Last trade - 16.10pm 07/10/2024 (20 minute delay)

BIT (ASX) Chart

$10 Billion Deal, page-11884

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

$10 Billion Deal, page-11884

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News